High efficiency microfluidic device for large scale engineered cell therapy manufacturing
用于大规模工程细胞治疗制造的高效微流体装置
基本信息
- 批准号:10693775
- 负责人:
- 金额:$ 29.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-06 至 2024-09-05
- 项目状态:已结题
- 来源:
- 关键词:3D PrintAllogenicAutologousAutomobile DrivingBenchmarkingBlood specimenCD3 AntigensCD8-Positive T-LymphocytesCell SeparationCell SurvivalCell TherapyCell physiologyCellsCellular immunotherapyClinicClinicalCollaborationsComplexConsumptionCryopreservationDevelopmentDevice DesignsDevicesDoseElectroporationEngineeringFlow CytometryGene DeliveryGene TransferGenesGenetic EngineeringGoalsHumanImmuneIndustry StandardInfusion proceduresInterventionLegal patentLettersMagnetic Bead TechnologyMethodsMicrofluidic MicrochipsMicrofluidicsMonoclonal Antibody HuM291Natural Killer CellsOpticsOutcomePatientsPerformancePeripheral Blood Mononuclear CellPhasePlant ResinsPolymersPopulationProcessProteinsQualifyingRecoveryRegulatory T-LymphocyteResearchSourceSystemT-LymphocyteT-Lymphocyte SubsetsTechnologyTestingTimeTransfectionVeinsViralWhole Bloodbiomaterial compatibilitychimeric antigen receptor T cellsclinical applicationcommercial applicationcostcost effective treatmentcytokinecytotoxicitydesignearly phase clinical trialengineered T cellsexperiencefabricationgene therapyimprovedindividual patientinstrumentmagnetic beadsmanufacturemanufacturing processmanufacturing technologymicrofluidic technologynovelnovel therapeuticsnucleic acid deliverypreclinical studypressureprototyperesearch and developmentresearch clinical testingscale upsuccess
项目摘要
The goal of this project is to demonstrate the feasibility of a gentle and high-yield microfluidic device for the
enrichment and capture of CD3+ T cells, for use in manufacturing autologous and allogenic engineered cell
therapies. Despite impressive clinical results CAR-T and other engineered cell therapies, manufacturing these
products is time consuming and costly. The ideal solution is one that could process whole blood, including target
cell enrichment and genetic engineering, with minimal human intervention. Indee. Inc. previously developed
Hydropore™, a microfluidic technology that has been optimized for the delivery of genes and constructs to
immune cells (e.g., T-cells). Hydropore™ is a reliable and rapid alternative to current transfection approaches
that yields tens to hundreds of millions of high-quality engineered cells negligible impact on cell viability and
function. However, immune cells must be isolated and enriched from whole blood prior to transfection, a
cumbersome, multistep process that introduces variability in the final cell product. Therefore, the Phase I
objective is to develop a microfluidic device that is similarly optimized for T cell isolation and enrichment. Studies
will focus on (1) the design and qualification of prototype device that is compatible with the Hydropore instrument,
(2) device optimization to maximize the viability and yield of isolated cells, and (3) demonstrating the performance
of the optimized T cell capture device in improving the quality and yield of engineered T cells. The success of
this project will demonstrate the feasibility of a high-yield T cell enrichment device that will not only improve the
source material for cellular immunotherapies but also make the manufacturing process more robust and reliable,
and ultimately providing more potent and cost-effective therapies that will benefit more patients.
该项目的目标是证明一种温和而高产的微流控装置的可行性
浓缩和捕获CD3+T细胞,用于制造自体和同种异体工程细胞
治疗。尽管CAR-T和其他工程细胞疗法的临床结果令人印象深刻,但制造这些
产品既耗时又昂贵。理想的解决方案是可以处理包括靶标在内的全血
细胞浓缩和基因工程,只需最少的人类干预。因迪。Inc.之前开发的
水孔™,一种微流控技术,已经针对交付基因和构建物进行了优化
免疫细胞(如T细胞)。水孔™是目前转染法的一种可靠和快速的替代方法
这将产生数千万到数亿高质量的工程细胞,对细胞活力的影响可以忽略不计
功能。然而,在转基因之前,必须从全血中分离和浓缩免疫细胞,a
繁琐的多步骤过程在最终细胞产品中引入了可变性。因此,第一阶段
目的是开发一种同样优化的微流控装置,用于T细胞的分离和浓缩。研究
将侧重于(1)与水孔仪兼容的原型装置的设计和鉴定,
(2)设备优化,以最大限度地提高分离细胞的活性和产量,以及(3)展示性能
优化的T细胞捕获装置在提高工程T细胞的质量和产量方面的应用。的成功之处
该项目将展示一种高产量T细胞浓缩设备的可行性,它不仅将改善
细胞免疫疗法的原始材料,也使制造过程更加坚固和可靠,
最终提供更有效、更具成本效益的疗法,使更多的患者受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ryan Pawell其他文献
Ryan Pawell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ryan Pawell', 18)}}的其他基金
Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetes
嵌合抗原受体调节性 T 细胞治疗 1 型糖尿病的快速、单步精密工程和临床前评估
- 批准号:
10477106 - 财政年份:2022
- 资助金额:
$ 29.59万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 29.59万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 29.59万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 29.59万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 29.59万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




